跳至主要内容
临床试验/NCT04500860
NCT04500860已完成1 期

Low Dose Tadalafil 5mg for Treatment of Female Overactive Bladder Syndrome :6 Months Follow up

Kasr El Aini Hospital1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2020年12月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
90
试验地点
1
主要终点
Efficacy of daily low dose tadalafil 5mg in treatment of female overactive bladder syndrome: 6 months follow up

研究概览

简要总结

Evaluation of use of low dose tadalafil 5 mg daily for treatment of female OAB syndrome

详细描述

90 female patients with overactive bladder syndrome divided into 3 groups group A subjected to daily low dose tadalafil 5 mg ,group B subjected to tolterodine and group C to placebo. They are evaluated as using OAB symptoms score for 6 months follow up

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

性别
Female
接受健康志愿者

入选标准

  • any female with overactive bladder syndrome, urgency with or without urgency urinary incontinence

排除标准

  • Active Urinary tract infection
  • neurologic abnormality
  • Pure Stress urinary incontinence

研究组 & 干预措施

Group A Tadalafil 5 mg

Active Comparator

30 patients subjected to Daily dose of tadalafil 5mg

干预措施: Low dose tadalafil 5 mg (Drug)

Group B Tolterodine

Active Comparator

30 patients subjected to tolterodine 4 mg daily

干预措施: Tolterodine 4 Mg Oral Capsule, Extended Release (Drug)

Group C placebo

Placebo Comparator

30 patients subjected to placebo daily

干预措施: Placebo (Drug)

结局指标

主要结局

Efficacy of daily low dose tadalafil 5mg in treatment of female overactive bladder syndrome: 6 months follow up

时间窗: 6 months

Evaluation of efficacy of tadalafil 5 mg

次要结局

未报告次要终点

研究者

发起方
Kasr El Aini Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Samer Morsy

Urology lecturer

Kasr El Aini Hospital

研究点 (1)

Loading locations...

相似试验

Low Dose Tadalafil for Treatment of Female OAB... | 临床试验